We develop and operate digital solutions for any chronic condition
where improved patient engagement and education
can deliver better treatment experiences and outcomes.
Digital therapeutics for improved patient experience
Our digital therapeutics are adapted to all chronic pathologies for which an increased patient engagement and personalized education can help improve the real-world treatment experience. Leveraging our Theraxium platform, expert teams and robust processes, we can support our life sciences partners across a variety of therapeutics areas. We are always on the lookout for new collaboration opportunities in oncology, immunology, neurology, rare diseases and beyond.
In diabetes, Voluntis designs digital therapeutics to support people with type 1 and type 2 diabetes and their care teams in the management of insulin therapy. Based on a mobile app for patients and a web application for the care team, our DTx solution provides automated insulin dose recommendations and coaching messages, while enabling the care team to remotely monitor progress. Real-time recommendations are based on the person’s blood glucose readings and other relevant diabetes-related data. The person with diabetes’ data are made available to the care team who can remotely monitor their progress toward their goal thanks to tailored notifications. This also enables providers to deliver personalized telemedicine services, a practice increasingly supported by payers worldwide.
Insulia®, a digital therapeutic Voluntis product FDA cleared and CE marked (CE0459) designed for people with type 2 diabetes, has been evaluated through clinical and real-world pilot studies.
Insulia® is a prescription-only software medical device intended for use by healthcare professionals and their type 2 adult diabetes patients as an aid in the management of diabetes. Insulia is only indicated for use with insulin detemir (Levemir U-100) once or twice daily, insulin degludec (Tresiba U-100) once daily, insulin glargine (Basaglar U-100, Lantus U-100, Semgle U-100 and Toujeo U-300) once daily and Human NPH once daily. Insulia should not be used for premixed insulin. Insulia should not be used in the following populations: pregnant women; non-adult patients; patients that are treated with a basal plus or a basal, bolus regimen (i.e multiple mealtime insulin injections per day or insulin pump therapy). Please carefully read product instructions and if in doubt, please consult your care team before use.
Other Therapeutic Areas
Get in touch!
Would like to partner with us? Got a question or a comment?Contact us